After four cycles of Pembrolizumab, one patient (Anti-Hbc positive, anti-Hbs negative and anti-Hbe negative) presented with >10 nonbloody bowel movements a day and the colon biopsies demonstrated a microscopic colitis (lymphocytic subtype). This evidence concerns the gene KRT88P and colitis.